Author

Y. Kanda

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Organism:chicken / avian· 1 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

M. Nishida· 2 shared S. Yanagida· 2 shared Y. Kato· 2 shared A. Hoshino· 1 shared A. Inoue· 1 shared A. Nishimura· 1 shared A. Ogawa· 1 shared A. Saito· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

M. Nishida

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

An engineered ACE2 decoy broadly neutralizes Omicron subvariants and shows therapeutic effect in SARS-CoV-2-infected cynomolgus macaques

E. Urano, Y. Itoh, T. Suzuki, T. Sasaki, J.-i. Kishikawa, K. Akamatsu, Y. Higuchi, Y. Sakai, T. Okamura, S. Mitoma, F. Sugihara, A. Takada, M. Kimura, M. Hirose, T. Sasaki, , T. Okamoto

This paper shows an engineered ACE2 decoy neutralizes Omicron subvariants and is effective in treating SARS-CoV-2 infection in macaques.

bioRxiv · Dec 29, 2022 · PreprintMicrobiology

Activation of the urotensin-II receptor by anti-COVID-19 drug remdesivir induces cardiomyocyte dysfunction

F.-Y. Wei, A. Inoue, A. Ogawa, S. Ohira, T. Ikuta, Y. Kato, S. Yanagida, Y. Ishii, Y. Kanda, M. Nishida

This study identifies remdesivir as a selective agonist of the urotensin-II receptor, linking its cardiotoxicity to receptor activation and genetic variants.

bioRxiv · Aug 8, 2022 · PreprintPharmacology & Toxicology

Clomipramine suppresses ACE2-mediated SARS-CoV-2 entry

Y. Kato, S. Yamada, K. Nishiyama, A. Satsuka, S. Re, D. Tomokiyo, J. M. Lee, T. Tanaka, A. Nishimura, K. Yonemitsu, H. Asakura, Y. Ibuki, Y. Imai, N. Kamiya, K. Mizuguchi, , M. Nishida

This study shows clomipramine inhibits SARS-CoV-2 entry into cardiomyocytes and synergizes with remdesivir to suppress infection.

bioRxiv · Mar 13, 2021 · PreprintPharmacology & Toxicology